Is VOMITING a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed VOMITING.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 118 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported VOMITING to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and VOMITING. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause VOMITING, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes VOMITING. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if VOMITING ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing VOMITING: 118
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where VOMITING is a reported side effect: 3.5446%

FDA reports of any drug causing VOMITING : 133249
Average percentage for all medicated patients where VOMITING is reported as a complication: 0.8351%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with VOMITING:

ASPIRIN (8253 patients)
HEPARIN SODIUM INJECTION (6847 patients)
BYETTA (5743 patients)
NEXIUM (5140 patients)
CHANTIX (4347 patients)
HUMIRA (4100 patients)
SEROQUEL (3964 patients)
PREDNISONE (3937 patients)
REMICADE (3883 patients)
FOSAMAX (3850 patients)
OMEPRAZOLE (3832 patients)
LASIX (3660 patients)
LISINOPRIL (3657 patients)
METFORMIN HCL (3580 patients)
ACETAMINOPHEN (3495 patients)
LIPITOR (3458 patients)
VIOXX (3435 patients)
METHOTREXATE (3290 patients)
SYNTHROID (3106 patients)
YAZ (2991 patients)
XANAX (2910 patients)
OXYCONTIN (2904 patients)
FOLIC ACID (2818 patients)
YASMIN (2812 patients)
IBUPROFEN (2722 patients)
FUROSEMIDE (2722 patients)
SIMVASTATIN (2638 patients)
ZOFRAN (2636 patients)
DIGOXIN (2606 patients)
PRILOSEC (2604 patients)
FORTEO (2584 patients)
CISPLATIN (2579 patients)
ATENOLOL (2571 patients)
ZOMETA (2558 patients)
PROTONIX (2441 patients)
ZOLOFT (2419 patients)
CYMBALTA (2403 patients)
AVONEX (2383 patients)
DURAGESIC-100 (2352 patients)
NEURONTIN (2344 patients)
HYDROCHLOROTHIAZIDE (2319 patients)
LANTUS (2286 patients)
DEXAMETHASONE (2277 patients)
SANDOSTATIN LAR (2274 patients)
COUMADIN (2273 patients)
ALBUTEROL (2272 patients)
FLUOROURACIL (2228 patients)
PLAVIX (2201 patients)
LEVOTHYROXINE SODIUM (2167 patients)
AMBIEN (2128 patients)
PAXIL (2121 patients)
LORAZEPAM (2120 patients)
LYRICA (2094 patients)
NORVASC (2062 patients)
POTASSIUM CHLORIDE (2061 patients)
ENBREL (2021 patients)
PREVACID (2021 patients)
VICODIN (2005 patients)
ATIVAN (2005 patients)
LEXAPRO (1985 patients)
CARBOPLATIN (1933 patients)
MORPHINE (1883 patients)
PREDNISOLONE (1865 patients)
RIBAVIRIN (1763 patients)
OXYCODONE HCL (1758 patients)
PERCOCET (1743 patients)
CELEBREX (1740 patients)
VITAMIN D (1715 patients)
TOPROL-XL (1669 patients)
GABAPENTIN (1602 patients)
ALLOPURINOL (1589 patients)
GLUCOPHAGE (1575 patients)
ZOCOR (1561 patients)
TYSABRI (1555 patients)
EXJADE (1551 patients)
AMLODIPINE (1534 patients)
PREDNISONE TAB (1534 patients)
GLEEVEC (1528 patients)
ACCUTANE (1524 patients)
INSULIN (1522 patients)
TRAMADOL HCL (1510 patients)
DECADRON (1509 patients)
BENADRYL (1495 patients)
DIANEAL (1493 patients)
FENTANYL (1488 patients)
XELODA (1488 patients)
CALCIUM (1483 patients)
PROZAC (1471 patients)
CRESTOR (1467 patients)
AREDIA (1462 patients)
HEPARIN SODIUM (1460 patients)
ZANTAC (1441 patients)
LEVAQUIN (1435 patients)
CAPECITABINE (1424 patients)
COMPAZINE (1409 patients)
WARFARIN SODIUM (1400 patients)
CLONAZEPAM (1392 patients)
DIOVAN (1391 patients)
CYCLOPHOSPHAMIDE (1385 patients)
EFFEXOR (1384 patients)
METOPROLOL TARTRATE (1352 patients)
ADVAIR DISKUS 100/50 (1350 patients)
OXALIPLATIN (1342 patients)
ALPRAZOLAM (1320 patients)
SINGULAIR (1319 patients)
TYLENOL (CAPLET) (1304 patients)
METOCLOPRAMIDE (1291 patients)
CLOZARIL (1290 patients)
REGLAN (1287 patients)
AVASTIN (1285 patients)
WELLBUTRIN (1278 patients)
LORTAB (1243 patients)
PEGASYS (1233 patients)
ONDANSETRON (1226 patients)
METFORMIN (1224 patients)
DIAZEPAM (1206 patients)
MORPHINE SULFATE (1189 patients)
ACTOS (1186 patients)
AMOXICILLIN (1177 patients)
KLONOPIN (1175 patients)
PEG-INTRON (1169 patients)
LANSOPRAZOLE (1166 patients)
RAMIPRIL (1151 patients)
TRAZODONE HCL (1151 patients)
RANITIDINE (1141 patients)
MULTI-VITAMINS (1133 patients)
SPIRONOLACTONE (1123 patients)
GLIPIZIDE (1122 patients)
VALIUM (1118 patients)
DILAUDID (1108 patients)
NEXAVAR (1108 patients)
MULTI-VITAMIN (1105 patients)
TYLENOL (1102 patients)
PROMETHAZINE (1099 patients)
COREG (1085 patients)
LAMICTAL (1085 patients)
PREMARIN (1083 patients)
ZYRTEC (1081 patients)
CELEXA (1072 patients)
VICTOZA (1068 patients)
BACTRIM (1027 patients)
NITROGLYCERIN (1004 patients)
HUMALOG (1003 patients)
TAXOL (1002 patients)
VITAMIN B-12 (1000 patients)
GLYBURIDE (996 patients)
EXELON (986 patients)
METOPROLOL (979 patients)
CITALOPRAM HYDROBROMIDE (976 patients)
AMARYL (974 patients)
TEGRETOL (969 patients)
REBIF (963 patients)
ENALAPRIL MALEATE (959 patients)
SUTENT (958 patients)
ZYPREXA (955 patients)
CIPROFLOXACIN (948 patients)
PANTOPRAZOLE (948 patients)
CLONIDINE (945 patients)
RISPERDAL (942 patients)
VALTREX (939 patients)
SPIRIVA (938 patients)
AVELOX (938 patients)
PACLITAXEL (935 patients)
CALCIUM CARBONATE (928 patients)
FLUCONAZOLE (925 patients)
COLACE (906 patients)
TOPAMAX (899 patients)
TAXOTERE (890 patients)
LEUCOVORIN CALCIUM (883 patients)
SOLIRIS (877 patients)
PLAN B ONE-STEP (877 patients)
AVANDIA (876 patients)
PHENERGAN (863 patients)
STRATTERA (861 patients)
ASCORBIC ACID (858 patients)
EFFEXOR XR (855 patients)
PEPCID (846 patients)
ZITHROMAX (845 patients)
DEPAKOTE (844 patients)
BEVACIZUMAB (839 patients)
VELCADE (830 patients)
ACTONEL (825 patients)
FERROUS SULFATE TAB (825 patients)
DOCETAXEL (824 patients)
BACLOFEN (818 patients)
MAGNEVIST (816 patients)
LOVENOX (816 patients)
AMITRIPTYLINE HCL (815 patients)
ALDACTONE (811 patients)
FLEXERIL (805 patients)
ALLEGRA (801 patients)
ALTACE (799 patients)
NAPROXEN (793 patients)
REVLIMID (785 patients)
FAMOTIDINE (780 patients)
PARACETAMOL (774 patients)
COZAAR (773 patients)
ACYCLOVIR (767 patients)
ARANESP (766 patients)
AUGMENTIN '125' (761 patients)
HYDROCODONE (758 patients)
KETEK (741 patients)
TEMAZEPAM (740 patients)
DOXORUBICIN HCL (735 patients)
HEPARIN (730 patients)
CYCLOSPORINE (730 patients)
ABILIFY (728 patients)
ULTRAM (723 patients)
ETOPOSIDE (721 patients)
FISH OIL (721 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about VOMITING and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.